NDATOPICALCREAM
Approved
Mar 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Data completeness
5/8 — Partial
ZYCLARA (imiquimod) by Bausch + Lomb is interferon inducers [moa]. First approved in 2010.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYCLARA (imiquimod) is a topical cream that works as an interferon inducer, activating the immune system to treat precancerous and cancerous skin lesions. It is indicated for actinic keratosis, basal cell carcinoma, lentigo maligna, and multiple other dermatologic and systemic cancers including cervical, vulvar, and anal dysplasia. The drug stimulates innate immune responses to eliminate abnormal cells and suppress tumor growth.
$115,000Part D
Peak4.0 years to LOEZYCLARA is at peak lifecycle with modest Part D spending ($115K annually), suggesting a niche dermatology product with limited commercial momentum compared to blockbuster oncology comparators.
Mechanism of Action
Interferon Inducers
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Started Oct 2025
18 enrolled
Cutaneous Basal Cell Carcinoma
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Started Apr 2020
0Mycosis Fungoides
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Started Aug 2017
33 enrolled
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar DysplasiaVulvar Intraepithelial Neoplasia (VIN)+4 more
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Started May 2017
50 enrolled
Cervical Intraepithelial Neoplasia 3
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Started Feb 2017
16 enrolled
Healthy
Worked on ZYCLARA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.